Knee PRP uses spun blood and may follow home care that hasn't helped

The exam shows how worn and steady the knee is

Tell the clinician when soreness began and what brings it on. Take any earlier exam or X-ray findings, along with your medicine list. Explain what exercise, braces, medicine, or other care did for you, and don't leave out an old injury.

Name one daily task you'd like to do with less trouble, since walking farther or climbing stairs is easier to judge than a broad hope. The exam and X-ray can show joint wear, swelling, motion, and how well the leg holds you. Those findings help frame the choice, but they can't predict relief.

The QC Kinetix visit should end with a plain answer

At QC Kinetix, a clinician can examine the joint and discuss non-surgical care. Its regenerative treatments include office care prepared after the clinic spins your blood and keeps plasma with extra clot-making platelets, though regenerative doesn't mean worn cartilage grows back. You shouldn't have to guess about that.

Ask about the blood draw, planned visits, full cost, and recovery advice. Mention aspirin, blood thinners, and medicine you use often. Don't stop any of them unless the clinician who manages them agrees, because a careful review can save trouble later.

Fever or sudden knee damage needs faster care

A very hot, swollen knee with fever may need urgent medical help. Spreading redness, drainage, or feeling ill also calls for prompt care. After an injury, a bent-looking joint or being unable to stand on that leg needs quick attention. Don't wait for a regular clinic visit.

Get timely care if the leg suddenly weakens, you hear a tendon pop, or the calf swells fast. Night soreness that keeps worsening also needs an exam, especially with weight loss or a cancer history. These signs don't prove something serious. They still need the right check.

Sources

1. The ESSKA-ICRS consensus applied the RAND/UCLA appropriateness method to 216 clinical scenarios for intra-articular PRP in knee OA. Only 84 scenarios (38.9%) were rated appropriate, 9 (4.2%) inappropriate and 123 (56.9%) uncertain. PRP was judged appropriate in patients aged 80 or under with KL grade 0-III osteoarthritis AFTER failed conservative non-injective or injective treatment; it was NOT considered appropriate as a first treatment, nor in KL grade IV (bone-on-bone) osteoarthritis, where 91.7% and 87.5% of scenarios respectively were uncertain.

   Kon E, de Girolamo L, Laver L, et al. — Platelet-rich plasma injections for the management of knee osteoarthritis: The ESSKA-ICRS consensus. Recommendations using the RAND/UCLA appropriateness method for different clinical scenarios. Knee Surgery, Sports Traumatology, Arthroscopy, 2024. DOI: 10.1002/ksa.12320.

2. The American Academy of Physical Medicine and Rehabilitation convened a technical expert panel that ran a structured literature review (2023, updated through June 2025) and a modified Delphi process, and issued five evidence-based clinical recommendations plus 11 consensus-based best practices for PRP in knee osteoarthritis. The statement is explicit that orthobiologic therapies 'remain an evolving area of practice' and that robust, dose-dependent randomized controlled trials are still needed to establish PRP's clinical effects.

   Borg-Stein J, Jayaram P, Colorado BS, et al. — AAPM&R guidance statement on platelet rich plasma for knee osteoarthritis. PM&R, 2026. DOI: 10.1002/pmrj.70144.

3. The 2019 ACR/Arthritis Foundation osteoarthritis guideline makes STRONG recommendations for exercise, weight loss in people with overweight or obesity, self-management programmes, tai chi, cane use, tibiofemoral bracing, topical and oral NSAIDs and intra-articular glucocorticoid injections for knee OA. Its conditional recommendations cover balance exercises, yoga, CBT, acupuncture, thermal modalities, radiofrequency ablation, acetaminophen, duloxetine and tramadol. Anything offered before a course of the strongly recommended options is being offered out of order.

   Kolasinski SL, Neogi T, Hochberg MC, et al. — 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis & Rheumatology, 2020. DOI: 10.1002/art.41142.

4. A systematic review of 105 clinical PRP studies in orthopaedics published 2006-2016 found that only 11 (10%) described the preparation protocol clearly enough for another investigator to repeat it, and only 17 (16%) reported any quantitative metric of the final PRP composition. The authors concluded that the current reporting of PRP preparation and composition does not allow the PRP products actually delivered to patients to be compared between studies.

   Chahla J, Cinque ME, Piuzzi NS, et al. — A Call for Standardization in Platelet-Rich Plasma Preparation Protocols and Composition Reporting: A Systematic Review of the Clinical Orthopaedic Literature. Journal of Bone and Joint Surgery (American), 2017. DOI: 10.2106/JBJS.16.01374.

5. A prospective cohort of 253 patients with KL 1-3 knee OA treated with three injections of 5 mL of autologous PRP found that platelet concentration positively correlated with clinical outcome. KOOS Pain improved more with higher platelet concentration at 2 months (P=.036), 6 months (P=.009) and 12 months (P=.014), with the same trend across other KOOS subscales and IKDC. The failure rate was 15.0% in the low-platelet group versus 3.3% in both the medium- and high-platelet groups, with no difference in adverse events.

   Boffa A, De Marziani L, Andriolo L, et al. — Influence of Platelet Concentration on the Clinical Outcome of Platelet-Rich Plasma Injections in Knee Osteoarthritis. American Journal of Sports Medicine, 2024. DOI: 10.1177/03635465241283463.

6. A systematic review of 29 randomized trials of PRP for knee OA that reported a platelet count, concentration or dose found that the 28 treatment arms with statistically significant positive outcomes at 6 months had a mean platelet dose of 5,500 (+/-474) x 10^6, while the three arms without a positive difference averaged 2,302 (+/-437) x 10^6 (P<.01). The same separation held at 12 months: 5,464 versus 2,253 x 10^6 (P<.05).

   Berrigan WA, Bailowitz Z, Park A, et al. — A Greater Platelet Dose May Yield Better Clinical Outcomes for Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis: A Systematic Review. Arthroscopy, 2025. DOI: 10.1016/j.arthro.2024.03.018.

7. In the RESTORE trial - the largest placebo-controlled PRP trial in knee osteoarthritis - 288 adults aged 50+ with symptomatic Kellgren-Lawrence grade 2-3 medial knee OA received three weekly intra-articular injections of leukocyte-poor PRP from a commercial system or saline placebo. At 12 months the mean change in knee pain was -2.1 points with PRP versus -1.8 with saline (difference -0.4; 95% CI -0.9 to 0.2; P=.17) against a minimum clinically important difference of 1.8, and the change in medial tibial cartilage volume was -1.4% versus -1.2% (difference -0.2%; 95% CI -1.9% to 1.5%; P=.81). Twenty-nine of 31 prespecified secondary outcomes showed no significant between-group difference. The authors concluded the findings do not support use of PRP for knee OA.

   Bennell KL, Paterson KL, Metcalf BR, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

8. Medicare's national coverage policy covers autologous platelet-rich plasma ONLY for patients with chronic non-healing diabetic, pressure and/or venous wounds, and only within an approved coverage-with-evidence-development clinical study. There is no Medicare national coverage for PRP in osteoarthritis or tendinopathy, which is why these injections are billed to the patient as cash-pay.

   Centers for Medicare & Medicaid Services — Autologous Platelet-rich Plasma (Coverage with Evidence Development). CMS.gov, 2024.